The company was founded as Genetix Pharmaceuticals in April 1992 by MIT faculty members Philippe Leboulch and Irving London.
In 2001, Walter Ogier was appointed Chief Executive Officer of Genetix Pharmaceuticals, and the company was focused on the development of LentiglobinTM for the treatment of sickle cell disease and thalassemia major (beta-thalassemia), the two most globally prevalent severe human genetic diseases.
In September 2010, preliminary results of clinical trials of LentiglobinTM at Hospital Necker in Paris France were published in the journal Nature by Drs. Marina Cavazzana-Calvo and Philippe Leboulch, scientific founder of Genetix Pharmaceuticals / bluebird bio. Stable (21 months) transfusion independence had been successfully achieved by a patient with severe beta-thalassemia who had been treated with Lentiglobin 2 years earlier. This represented the first-ever long term correction of a major human genetic disease by gene therapy. Nature 467, 318–322 (2010)
Also in September 2010, the company was renamed bluebird bio and Nick Leschly was named chief executive officer.
In June 2013, the company became a public company via an initial public offering, raising $116 million.
In June 2014, the company acquired Precision Genome Engineering Inc. for up to $156 million.
In November 2017, Celgene, now Bristol-Myers Squibb (BMS), announced a collaboration with bluebird bio regarding bb2121 Anti-BCMA CAR-T Cell Therapy. In May 2020 the FDA issued a refusal to file letter to BMS and bluebird bio’s marketing application seeking approval of idecabtagene vicleucel (ide-cel) for patients with heavily pre-treated relapsed and refractory multiple myeloma. In September 2020, the FDA accepted bluebird’s marketing application for ide-cel in and established a PDUFA goal date of March 27, 2021. US approval of ide-cel by March 31, 2021 is one of the required remaining milestones of the contingent value rights (CVR) issued upon the close of Bristol Myers Squibb’s purchase of Celgene in 2019. Ide-cel is a BCMA-directed genetically modified autologous CAR-T-cell immunotherapy.
In August 2018, the company announced a collaboration with Regeneron Pharmaceuticals to discover, develop and commercialize new cell therapies for cancer.
On October 8th, 2021 bluebird bio, Inc. announced the impending spinoff of a new public company 2seventy bio focused on oncology. The spin-off is expected to be completed by early November 2021. bluebird bio’s corporate filing announced they have appointed Najoh Tita-Reid and Sarah Glickman to the bluebird bio board of directors. Ms. Glickman will be a member of the board of directors of 2seventy bio and will step down from the bluebird bio board of directors when the new arrangement goes into effect.
Bluebird Bio — факторы роста и падения акций
⚠️ Если вы считаете, что какой-то фактор роста/падения больше не является актуальным, выделите его и нажмите CTRL+ENTER на клавиатуре, чтобы сообщить нам.
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer.
bluebird bio Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$11.31|
|52 Week High||US$53.68|
|52 Week Low||US$10.35|
|1 Month Change||-43.17%|
|3 Month Change||-39.94%|
|1 Year Change||-75.13%|
|3 Year Change||-90.29%|
|5 Year Change||-81.03%|
|Change since IPO||-57.97%|
Recent News & Updates
bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely
There’s no doubt that money can be made by owning shares of unprofitable businesses. For example, although…
bluebird bio: Like A Bird In The Middle Of The Deep Blue Sea
bluebird bio was a pioneer in the gene therapy space.Unfortunately, it hasn’t been a commercial success.The upcoming spinoff doesn’t raise confidence in bluebird’s future either.
|BLUE||US Biotechs||US Market|
Return vs Industry: BLUE underperformed the US Biotechs industry which returned 10.7% over the past year.
Return vs Market: BLUE underperformed the US Market which returned 31.1% over the past year.
|BLUE Average Weekly Movement||15.4%|
|Biotechs Industry Average Movement||8.5%|
|Market Average Movement||5.8%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.2%|
Stable Share Price: BLUE is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: BLUE’s weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma.
bluebird bio Fundamentals Summary
|BLUE fundamental statistics|
Earnings & Revenue
|BLUE income statement (TTM)|
|Cost of Revenue||US$605.49m|
Last Reported Earnings
Sep 30, 2021
|Earnings per share (EPS)||-12.33|
|Net Profit Margin||-1,610.78%|
How did BLUE perform over the long term?
See historical performance and comparison
Is bluebird bio undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BLUE’s fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BLUE’s fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BLUE is unprofitable, so we can’t compare its PE Ratio to the US Biotechs industry average.
PE vs Market: BLUE is unprofitable, so we can’t compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BLUE’s PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BLUE is good value based on its PB Ratio (0.9x) compared to the US Biotechs industry average (3.1x).
- Zynteglo: In June 2019, the company received approval from the European Commission to market in the EU betibeglogene autotemcel (Zynteglo), a medication for the treatment of the beta thalassemia group of inherited blood disorders. Bluebird has yet to seek FDA approval for the treatment. The FDA granted Zynteglo orphan drug and breakthrough therapy designations for the treatment of TDT.
Bluebird Bio — описание компании
Bluebird Bio, Inc., базирующаяся в Кембридже, штат Массачусетс, является биотехнологической компанией, которая разрабатывает генную терапию для лечения тяжелых генетических заболеваний и рака.
How is bluebird bio’s financial position?
Financial Position Analysis
Short Term Liabilities: BLUE’s short term assets ($832.3M) exceed its short term liabilities ($266.6M).
Long Term Liabilities: BLUE’s short term assets ($832.3M) exceed its long term liabilities ($202.6M).
Debt to Equity History and Analysis
Debt Level: BLUE is debt free.
Reducing Debt: BLUE has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLUE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BLUE has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 23.7% each year.
- Official website
- Business data for bluebird bio, Inc.:
What is bluebird bio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BLUE’s dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BLUE’s dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLUE’s dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLUE’s dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BLUE’s dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Nick Leschly has been the Chief Executive Officer and President at bluebird bio, Inc. (alternate name Genetix Pharmaceuticals Inc.) since September 2010. Mr. Leschly served as Interim President at blue…
CEO Compensation Analysis
Compensation vs Market: Nick’s total compensation ($USD6.24M) is above average for companies of similar size in the US market ($USD2.19M).
Compensation vs Earnings: Nick’s compensation has been consistent with company performance over the past year.
Experienced Management: BLUE’s management team is considered experienced (4.5 years average tenure).
Experienced Board: BLUE’s board of directors are seasoned and experienced ( 10.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.6%.
bluebird bio, Inc.’s employee growth, exchange listings and data sources
- Name: bluebird bio, Inc.
- Ticker: BLUE
- Exchange: NasdaqGS
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$792.913m
- Shares outstanding: 70.11m
- Website: https://www.bluebirdbio.com
Number of Employees
- bluebird bio, Inc.
- 60 Binney Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/10 23:28|
|End of Day Share Price||2021/11/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.